New drug combo aims to extend life in tough lung cancer
NCT ID NCT05874401
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether adding trilaciclib before standard chemotherapy (topotecan) can help people with extensive-stage small cell lung cancer live longer. About 302 participants will receive either trilaciclib or a placebo before their chemo, and researchers will compare overall survival. The trial is double-blind, meaning neither patients nor doctors know who gets the real drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trilaciclib (a drug given before chemotherapy to protect healthy cells)
What this could lead to
If it works, this could show that trilaciclib helps people with advanced small cell lung cancer live longer or have better outcomes when combined with standard chemotherapy.
What could go wrong
This is a Phase 4 trial, but it's testing non-inferiority (whether trilaciclib is at least as good as placebo). The drug may not improve survival, and side effects from chemotherapy remain a risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital
RECRUITINGSeville, Spain
Contact